Lipedema
A distinct, painful, progressive adipose storage disease — not obesity, not lymphedema. Recognizing it changes everything about how we can start treating it.
Obesity Medicine 2026 · The Heart of Obesity Care
Unlocking Lipedema: Diagnosis, Treatment & Hope
The Doctor Doug Podcast, Ep #9 — a full conversation with Dr. Leslyn Keith, OTD, CLT, co-editor of Lipedema: Principles & Practice of Diagnosis and Treatment.
Six ideas that will change how you see this adipose tissue disease.
Click any card for a quick reference summary with key pearls and references.
What it looks like
Disproportionate fatty deposits on the arms, legs, hips, buttocks — sometimes abdomen and torso. Lumpy, nodular tissue, often pronounced behind the knees and elbows.
Pathophysiology
Lymphatic stagnation, chronic inflammation, estrogen-receptor β, microvascular fragility, neurogenic pain — a multi-system adipose disease.
Keith 2024 Diagnostic Criteria
Five essential features that make the diagnosis. If all five are present, it's lipedema — full stop.
Lipedema vs. Lymphedema
Bilateral symmetry, spared hands/feet, negative Stemmer sign — the clinical anchors that separate these often-confused conditions.
Comorbidities & Overlap
Lipedema patients are often more metabolically healthy than you'd expect — unless obesity co-exists. Combination presentations matter.
2024 Guidelines Update
What's new since the 2021 US Standard of Care: the German S2k guideline and the Lipedema World Alliance Delphi Consensus reframe the disease.
Treatment that works.
The 2024 German S2k guideline and the 2026 Lipedema World Alliance Delphi Consensus converge on the same picture: lipedema is chronic (lifelong) and requires a multidisciplinary approach. Conservative first, surgery last — with adjunctive pharmacotherapy increasingly recognized in between.
Foundation of Care
Complete Decongestive Therapy (CDT)
Medical Compression
Carb-Restricted Nutrition
Physical Activity
Psychological Support
Obesity Treatment (if co-occurring)
Adjuvant Therapies
Intermittent Pneumatic Compression
Manual Therapies
Vibration Therapy
Where the Standard of Care meets the GLP-1 era.
Herbst's 2021 SOC recognizes sympathomimetic amines as a pharmacologic option for refractory lipedema — a position that predates the modern GLP-1 era. Here is the case for each, calibrated to the evidence.
Low-Dose Dextroamphetamine
The Herbst SOC's named pharmacologic option for the lipedema-specific symptom complex. Mechanistic rationale is strong; evidence base is thin but coherent.
- α/β-adrenergic adipocyte stimulation → lipolysis of fibrotic, diet-resistant adipose
- Adrenergic agonism of lymphatic smooth muscle → enhanced contractility and pumping (McHale 1987; Sjöberg 1987)
- Mild natriuretic / diuretic effect addressing the fluid-retention component (Speller & Streeten 1964)
Phentermine requires higher doses and tends to downregulate adrenergic receptors, requiring drug holidays. d-amphetamine works at much lower doses without that tachyphylaxis pattern — sustaining lipolytic and lymphatic effects long-term.
- Herbst, Abu-Zaid, Fazel (Med Res Arch 2019): retrospective self-report study of women with lipedema and patients with Dercum's on sympathomimetic amines. At ~3 months: >90% reported overall symptom improvement, 77% reported localized fat reduction, 63% reduced lower-leg swelling. Cognitive improvements common. Side effects: insomnia 17%, palpitations 17%, abdominal pain 2%.
- Ghazala, Bilal, Herbst et al. (Am J Med 2018): low-dose d-amphetamine (10–20 mg/day) regressed hepatic fat from 16% → 4% in one Dercum case; resolved subcutaneous fat deposits at ~1 year in another.
- No RCT exists. Evidence quality is uncontrolled self-report and case reports. Herbst's own SOC hedges: "take only if benefits outweigh risks."
Start: 2.5–5 mg IR PO once daily, AM
Target: 10–20 mg/day total, often AM + early afternoon to avoid insomnia
Premise: very low doses sustain adrenergic effects on adipocytes and lymphatics without receptor downregulation
- Schedule II — DEA prescribing, monthly scripts, state PDMP check, no refills
- Cardiovascular screen before starting; avoid in uncontrolled HTN, structural heart disease, hyperthyroidism, glaucoma, MAOI use, history of stimulant misuse
- Pregnancy contraindicated; verify contraception in reproductive-age women
- Off-label for lipedema — document indication, prior conservative care optimization, and informed consent
GLP-1 Receptor Agonists — Tempered View
Clinically observed to help in lipedema-overlap patients with co-existing obesity. The evidence base for lipedema specifically is anecdotal.
- No RCT in lipedema. No prospective study in lipedema. No published mechanistic rationale specific to lipedematous adipose.
- Clinical-observation reports (Carmody & Keith, OMA 2026 lecture) of improved lipedema symptoms in patients started on a GLP-1 for co-existing obesity.
- Herbst's 2021 SOC predates the modern GLP-1 era and does not feature them. Her current framework prioritizes sympathomimetics for the lipedema-specific symptom complex.
- Treat the comorbidity, not the lipedema. Use a GLP-1 for the same reasons as in non-lipedema patients: obesity, T2DM, MASLD, CV risk.
- Expect lipedema fat to behave like lipedema fat. Limb volume, pain, and tissue texture often unchanged even when the scale moves.
- Re-examine at 6 months: if obesity has receded and lipedema-specific symptoms persist, the plan hasn't failed — the diseases have separated.
- Combination with low-dose d-amphetamine is described anecdotally; no published evidence base.
For the patient with lipedema + obesity, a GLP-1 RA is justified by the obesity. For the patient with pure lipedema and unremarkable metabolic profile, the evidence does not yet support GLP-1 therapy — and Herbst's mechanistic case for low-dose sympathomimetics is the stronger lipedema-specific argument.
Thin evidence, persistent rationale — use as adjuncts, not substitutes.
None of these has an RCT in lipedema specifically. Each appears in the Herbst 2021 SOC or the patient-community literature with mechanistic logic worth taking seriously. Check baseline labs where applicable and layer onto — not in place of — the foundation work in Tier 1.
Selenium
Vitamin D
Guaifenesin
Surgical Intervention
Lymph-Sparing Tumescent Liposuction
Herbst KL et al. Standard of care for lipedema in the United States. Phlebology. 2021;36(10):779–796.
Herbst KL, Abu-Zaid L, Fazel M. Question-based Self-reported Experience of Patients with SAT Disease Prescribed Sympathomimetic Amines. Medical Research Archives. 2019;7(6).
Ghazala S, Bilal J, Ross E, Riaz IB, Kalb B, Herbst KL. Low-Dose d-Amphetamine Induced Regression of Liver Fat Deposits in Dercum Disease. Am J Med. 2018;131(10):e409–e413.
McHale NG, Allen JM, Iggulden HL. Mechanism of alpha-adrenergic excitation in bovine lymphatic smooth muscle. Am J Physiol. 1987;252(5 Pt 2):H873–8.
Speller PJ, Streeten DH. Mechanism of the Diuretic Action of D-Amphetamine. Metabolism. 1964;13:453–65.
Faerber G et al. JDDG. 2024;22(9):1303-1315.
Kruppa P et al. Nat Commun. 2026;17:427.
Carmody M, Keith L. Lipedema and Obesity: Distinct Diagnoses, Distinct Care. Obesity Medicine 2026 conference lecture.
Kasseroller RG, Schrauzer GN. Treatment of secondary lymphedema of the arm with physical decongestive therapy and sodium selenite: a review. Am J Ther. 2000;7(4):273–9.
Bruns F, Büntzel J, Mücke R, et al. Selenium in the treatment of head and neck lymphedema. Med Princ Pract. 2004;13(4):185–90.
Amand RP, Marek C. What Your Doctor May Not Tell You About Fibromyalgia: The Revolutionary Treatment That Can Reverse the Disease. Warner Books, 1999. (Guaifenesin protocol — extrapolated use in lipedema patient communities.)
Diagnostic Workup of Suspected Lipedema
The workflow follows the Keith et al. 2024 research case definition, integrated with the 2024 German S2k guideline and the 2026 Lipedema World Alliance Delphi Consensus. Click any step to expand the rationale.
01History — Onset, Pain, Diet Response, Family
When did the disproportion start? Puberty, pregnancy, or perimenopause is classic. Ask specifically.
What does the fat feel like? Heaviness, pressure sensitivity, spontaneous pain. Most patients describe it as "congested" or "tight" long before they use the word pain.
Diet history: prior weight-loss efforts, trajectory of the upper body vs. lower body with each attempt. Lipedema classically resists diet.
Family history: "I have my aunt's legs" is a pearl. No confirmed gene cluster yet, but the familial pattern is real.
02Apply the Keith 2024 Essential Criteria
All five must be present for a clinical diagnosis:
• Female sex
• Pain or tenderness in affected tissue
• Disproportionate adipose distribution (lower body ± arms)
• Skin and tissue changes (nodular texture, cuffing)
• Lack of response to traditional diet/exercise
Female and pain are non-negotiable. Without pain, it isn't lipedema — it's something else.
03Texture Exam — Roll the Tissue
Technique: roll a 2-inch fold of mid-proximal upper arm between thumb and index/middle finger; repeat with a 1-inch fold at the lower mid-distal arm. Also palpate the fat lobule behind the knee.
Normal fat: soft, bouncy, smooth.
Stage I–II lipedema: soft with hard lentil- to chickpea-sized granules.
Stage III lipedema: tough tissue with larger granules, matted, poorly pliable.
Staging note: stage describes tissue architecture, not symptom severity. A stage I patient can have debilitating pain.
04Look for Ankle/Wrist Cuffing and Negative Stemmer
Cuffing: abrupt band-like transition at the ankle or wrist, with the foot/hand spared. Ranges from subtle to severe.
Stemmer sign: attempt to pinch a skinfold over the dorsum of the 2nd toe. Negative (pinchable) in lipedema; positive (cannot pinch) in lymphedema.
Non-pitting edema is typical in lipedema; pitting raises suspicion for converted lipo-lymphedema or a separate edematous process.
05Assess Comorbidities and Combination Presentations
Check obesity status separately. BMI, waist-to-height ratio, percent body fat, visceral/android fat. 70–80% of lipedema patients also carry an obesity diagnosis.
Screen for lipo-lymphedema: new pitting, unilateral progression, skin changes consistent with chronic lymphatic overload.
Screen for: hypermobility/EDS, MCAS, CVI, hypothyroidism, depression, anxiety. Psychological distress and weight-stigma injury are nearly universal.
Rule out other causes of the presenting feature: venous disease, primary lymphedema, Cushing, hypothyroid myxedema, anti-coagulation bruising.
06Document, Validate, and Coordinate
Name the disease in the chart and to the patient. Validation reverses years of diagnostic invalidation and opens the door to treatment adherence.
Assemble the team: Certified Lymphedema Therapist (CLT), nutrition (carb-restriction-literate), mental health, vascular/orthopedic as indicated, surgical lipedema specialist if indicated.
Set realistic expectations: conservative care first, symptom-focused rather than scale-focused. Progress, not cure.
Resources to learn more, get care, or to refer patients.
The clinical and community ecosystem most clinicians don't realize exists. Each entry is vetted against The Lipedema Project, the Lipedema Foundation, the Fat Disorders Resource Society, or the practice's own materials.
Patient resources & communities
Do You Have Lipedema? — quiz
The Doctor Doug Podcast Ep #9 — with Dr. Leslyn Keith
The Lipedema Project
The Disease They Call Fat
Lipedema Foundation
Fat Disorders Resource Society
Lipedema Simplified
Lipedema Summit 2026
Lipedema: Principles and Practice of Diagnosis and Treatment
Lipedema & Me — Find a Surgeon
Get an evaluation at Forte.
I can evaluate and manage lipedema and help prepare patients for surgery. We have a multidisciplinary team to help with many aspects of the care.